Morepen Laboratories has introduced Empamore, a new medication designed to treat Type 2 Diabetes, Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. India has a high number of diabetes cases with over 101 million people affected. Empamore aims to offer an affordable and high-quality treatment to help people manage their health better.
Empamore contains Empagliflozin, a well-known medicine for diabetes control. Morepen produces this at its USFDA-approved facility, ensuring global quality standards. The product range includes:
With diabetes cases in India rising, Morepen’s cost-effective solution makes quality treatment more accessible.
Morepen aims to reduce financial stress for diabetes patients by selling Empamore at 90% lower costs compared to existing brands. The company focuses on expanding healthcare access by ensuring the medicine is widely available at reasonable prices. Ashutosh Sharma, Vice President of Sales & Marketing at Morepen Laboratories, expressed during the launch, “At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without Financial strain. This aligns with our commitment to empower people to take charge of their health.”
Morepen has a strong history in diabetes management, having installed over 12.33 million glucometers and sold 1.65 billion blood glucose strips. With a global presence in 82 countries, the company continues to innovate and bring affordable healthcare solutions to both India and the world.
As of March 18, 2025, at 1:30 PM, the shares of Morepen Laboratories Ltd are trading at ₹48.99 per share, reflecting a profit of 14.36% from the previous day’s closing price. Over the past month, the stock has registered a loss of 1.90%. The stock’s 52-week high stands at ₹100.90 per share, while its low is ₹40.20 per share.
Empamore is a step towards affordable and accessible healthcare for diabetes patients. By providing cost-effective and high-quality treatment, Morepen is making it easier for people to manage their health without financial strain.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 18, 2025, 4:27 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
